DXCM vs. MMM, BAX, ABMD, ABT, ISRG, SYK, BSX, MDT, BDX, and EW
Should you be buying DexCom stock or one of its competitors? The main competitors of DexCom include 3M (MMM), Baxter International (BAX), Abiomed (ABMD), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Medtronic (MDT), Becton, Dickinson and Company (BDX), and Edwards Lifesciences (EW).
DexCom (NASDAQ:DXCM) and 3M (NYSE:MMM) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, community ranking, earnings, analyst recommendations and valuation.
DexCom has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Comparatively, 3M has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.
In the previous week, DexCom had 3 more articles in the media than 3M. MarketBeat recorded 21 mentions for DexCom and 18 mentions for 3M. DexCom's average media sentiment score of 0.89 beat 3M's score of 0.61 indicating that DexCom is being referred to more favorably in the media.
DexCom has a net margin of 16.82% compared to 3M's net margin of -21.57%. 3M's return on equity of 95.80% beat DexCom's return on equity.
DexCom received 63 more outperform votes than 3M when rated by MarketBeat users. Likewise, 71.86% of users gave DexCom an outperform vote while only 59.53% of users gave 3M an outperform vote.
97.8% of DexCom shares are owned by institutional investors. Comparatively, 65.3% of 3M shares are owned by institutional investors. 0.3% of DexCom shares are owned by insiders. Comparatively, 0.3% of 3M shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
DexCom has higher earnings, but lower revenue than 3M. 3M is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.
DexCom presently has a consensus price target of $140.94, suggesting a potential upside of 18.66%. 3M has a consensus price target of $108.55, suggesting a potential upside of 8.39%. Given DexCom's stronger consensus rating and higher probable upside, equities analysts clearly believe DexCom is more favorable than 3M.
Summary
DexCom beats 3M on 15 of the 19 factors compared between the two stocks.
Get DexCom News Delivered to You Automatically
Sign up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DXCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
